Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03179878 | Safety and Tolerability of SYNB1020-CP-001 | PHASE1 | COMPLETED | 52 | — | — | Jun 16, 2017 | Apr 11, 2018 | May 12, 2021 | 1 | United States |
Will be measured by assessing nature and frequency of AEs, Laboratory Assessments, and ECGs
| Arm | Type | Description |
|---|---|---|
| SYNB1020 | EXPERIMENTAL | SYNB1020 |
| Placebo | PLACEBO_COMPARATOR | 100 mL masking solution |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| SYNB1020 | DRUG | Investigational Product |
Key Inclusion Criteria: * Age 18 to 64 years * Healthy volunteer Males and Females; Females must be of non childbearing potential * Able and willing to complete informed consent process * Available for and agree to all study procedures * Screening Labs within normal range Key Exclusion Criteria: ...